Actively Recruiting
Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-03-16
30
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
Sponsors
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD. The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.
CONDITIONS
Official Title
Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with kidney failure on peritoneal dialysis (PD), both new and ongoing treatments
- Stable prescription of dextrose-based dialysis solutions for at least 3 months
- Classified as high or high-average transporters by peritoneal equilibrium test (PET)
You will not qualify if you...
- History of euglycemic ketoacidosis
- Known allergy to canagliflozin
- Active peritonitis or tunnel infection
- Scheduled kidney transplant within the next 6 months
- Severe liver cirrhosis (Child-Pugh class C)
- Recurrent severe genital or urinary infections
- Use of digoxin, phenobarbital, phenytoin, rifampin, or ritonavir that cannot be safely stopped
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Institute-McGill University Health Center
Montreal, Quebec, Canada
Actively Recruiting
Research Team
E
Efrosyne Tsirella
CONTACT
N
Norka Rios
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here